News Centre
- Global
-
2021-08-05 09:08The First Domestic TF ADC Drug Approved for Clinical Use: LEPU BIOPHARMA MRG004AMore -
2021-07-22 10:01MRG003 Hopefully Reshape the Therapeutic Landscape of Advanced NSCLCMore -
2021-07-19 17:42LEPU BIOPHARMA Conducting a Clinical Trial of MRG002, Bringing New Hopes for HER2-positive Breast Cancer PatientsMore -
2021-07-15 15:04Lepu’s NDA for anti-PD-1 antibody accepted ahead of Hong Kong IPOMore -
2021-07-05 11:46The NDA for Pucotenlimab (HX008) of LEPU BIOPHARMA as the second-line treatment for melanoma was formally accepted by the CDEMore -
2021-06-07 15:12At the ASCO meeting in 2021, Lepu Biopharma reported on the progress of two clinical studies of HX008.More
